Moderna and Merck's mRNA vaccine, combined with Keytruda, shows promise in reducing melanoma recurrence. Results were presented at the ESMO congress in Madrid.
Vaccine trial shows promising results
In August of last year, Moderna and Merck shared early positive results from a phase 3 study testing their therapeutic messenger RNA vaccine on patients who had surgery for high-risk melanoma. The vaccine, used alongside the immunotherapy drug Keytruda, showed a significant reduction in the risk of cancer returning or spreading compared to Keytruda alone.Study details presented at ESMO
The full results of the study were shared during the annual meeting of the European Society for Medical Oncology (ESMO), which took place in Madrid, Spain, from October 23 to 27. These findings highlight the potential of personalized messenger RNA vaccines in treating certain cancers.Personalized vaccine manufacturing
The vaccine is made specifically for each patient based on the unique characteristics of their tumor. This customization aims to enhance the immune system’s ability to recognize and attack cancer cells effectively.Future implications for cancer treatment
Experts suggest that if these results are confirmed in larger studies, the combination of personalized mRNA vaccines and existing immunotherapies could represent a major advancement in the treatment of high-risk melanoma and potentially other cancers.
